[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-rhinosinusitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-rhinosinusitis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,41,66,94,121,149],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100549847","phase-2-long-term-safety-and-efficacy-of-tqh2722-injection-in-the-treatment-of-chronic-sinusitis-with-or-without-nasal-polyps-100549847",false,"NCT06439381","Long-term Safety and Efficacy of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps","A Multicenter, Randomized, Continuing Trial to Evaluate the Long-term Safety and Efficacy of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps","Inclusion Criteria:\n\n1. Inclusion Criteria of Part A\n\n   * Sign informed consent before the test to fully understand the purpose, process and possible adverse reactions of the test;\n   * Age 18-75 years old (including the threshold), male or female;\n   * Enroll in the clinical study of TQH2722 for chronic sinusitis with or without nasal polyps (study number TQH2722-II-02) and meet the following criteria \"a\" or \"b\" :\n\n     1. Subjects completed prescribed treatment as required and completed Part A end of study (EOS) visit;\n     2. The subjects withdrew early due to poor compliance or other objective reasons other than TQH2722-related AE, and completed the early exit interview according to the plan, and the influencing factors that led to the subjects' early termination of the main study treatment have disappeared\u002Fno longer affected the subjects' participation in the continuation study as assessed by the investigators and sponsors.\n\n   Note: If protocol window period requirements are met, examination results from subject's main study EOS\u002F early exit visit may be used as screening\u002Fbaseline examination for this study.\n   * Subjects had used a more stable dose of nasal glucocorticoids (INCS) for more than 4 weeks prior to screening (for subjects who had used other INCS prior to screening than intranasal Mometasone furoate nasal spray (MFNS), subjects were willing to switch to MFNS during the study);\n   * Subjects agree not to have a family plan for 6 months from the date of signing the informed consent to the last dose, and must use effective non-drug contraception with their sexual partners of childbearing age.\n2. Inclusion Criteria of Part B\n\n   * Sign informed consent before the test to fully understand the purpose, process and possible adverse reactions of the test;\n   * Age 18-75 years old (including the threshold), male or female;\n   * Enroll in the clinical study of TQH2722 for chronic sinusitis with or without nasal polyps (study number TQH2722-II-02) and meet the following criteria \"a\" or \"b\" :\n\n     1. Subjects completed prescribed treatment as required and completed Part B EOS visit;\n     2. The subjects withdrew early due to poor compliance or other objective reasons other than TQH2722-related AE, and completed the early exit interview according to the plan, and the influencing factors that led to the subjects' early termination of the main study treatment have disappeared\u002Fno longer affected the subjects' participation in the continuation study as assessed by the investigators and sponsors.\n\nNote: If protocol window period requirements are met, examination results from subject's main study EOS\u002F early exit visit may be used as screening\u002Fbaseline examination for this study.\n\n* Subjects had used a more stable dose of nasal glucocorticoids (INCS) for more than 4 weeks prior to screening (for subjects who had used other INCS prior to screening than intranasal Mometasone furoate nasal spray (MFNS), subjects were willing to switch to MFNS during the study);\n* Subjects agree not to have a family plan for 6 months from the date of signing the informed consent to the last dose, and must use effective non-drug contraception with their sexual partners of childbearing age.\n\nExclusion Criteria:\n\n* In the main study (TQH2722-II-02), a TQH2722-related SAE occurred or TQH2722-related AE led to the discontinuation of TQH2722 therapy, and after discussion between the investigator and sponsor, the subject was deemed unsuitable for continuation of TQH2722 therapy.\n* The subjects had poor compliance in the main study, and the researchers judged that they could not complete the continuing study.\n* During the main study (TQH2722-II-02), any severe progression or poorly controlled concomitant disease (such as asthma exacerbation requiring adjustment of background medication) is identified and the subject is deemed unfit to participate by the principal investigator;\n* Any of the following laboratory test values are abnormal during the screening period:\n\n  1. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\>2.5 upper limit of normal (ULN);\n  2. Total bilirubin \\> 2 x ULN (except indirect bilirubin elevation secondary to Gilbert syndrome);\n  3. Creatinine \\> 1.5×ULN;\n* Any medical condition, including but not limited to cardiovascular, gastrointestinal, liver, kidney, neurological, musculoskeletal, infectious, endocrine, metabolic, hematological, psychiatric, or major limb disorders, that the investigator believes is unstable and may affect the patient's safety throughout the study period, or affect the study results or their interpretation, or interfere with the patient's ability to complete the entire study process.For example, but not limited to: ischemic heart disease, left ventricular failure, arrhythmia, uncontrolled hypertension, uncontrolled hyperglycemia, cerebrovascular disease, etc.;\n* Patients with active autoimmune diseases (including, but not limited to, Hashimoto thyroiditis, Graves' disease, inflammatory bowel disease, primary biliary cholangitis, systemic lupus erythematosus, multiple sclerosis and other neuroinflammatory diseases, psoriasis vulgaris, rheumatoid arthritis);\n* Known or suspected immunosuppressed individuals, including but not limited to a history of invasive opportunistic infections (e.g., histoplasmosis, listeriosis, coccidioidomycosis, pulmonary cyst disease, aspergillosis), even if the infection has resolved;\n* Subjects with active malignant tumors or a history of malignant tumors:Patients with basal cell carcinoma, skin localized squamous cell carcinoma, or cervical carcinoma in situ who had completed curative treatment for at least 12 months prior to visit 1 could be enrolled in this study; patients with other malignancies could be enrolled if they had completed curative treatment for at least 5 years prior to visit 1;\n* A history of active pulmonary tuberculosis within 12 months prior to screening;\n* Active hepatitis was present at the screening stage, either hepatitis B surface antigen (HBsAg) positive, hepatitis B core antibody (HBcAb) positive and Hepatitis B Virus-DNA positive, or Hepatitis C Virus (HCV) antibody positive and HCV-RNA positive; or human immunodeficiency virus (Anti-HIV) positive, or treponema pallidum antibody (Anti-TP) positive (if the treponema pallidum serological test is positive, then further non-treponema pallidum serological test is performed, the latter is negative and the investigator determines that patients who have been infected with syphilis in the past but have been cured are eligible for inclusion);\n* Diagnosis of helminthic infection within 6 months prior to the screening period, failure to receive standard treatment or failure to respond to standard treatment;\n* Subjects who received the following treatments:\n\n  1. Had sinus surgery or nasal sinus surgery within 6 months prior to screening (visit 1).\n  2. Received monoclonal antibody therapy within 8 weeks or 5 half-lives prior to screening (whichever is longer);\n  3. Received immunosuppressive therapy (including but not limited to cyclophosphamide, cyclosporine, interferon gamma, azathioprine, methotrexate, mycophenolate and tacrolimus) within 8 weeks or 5 half-lives prior to screening, whichever is longer;\n  4. Use of other non-biological agents within 8 weeks or 5 half-lives (whichever is longer) prior to screening;\n  5. Intravenous immunoglobulin (IVIG) therapy and\u002For plasma exchange within 30 days prior to screening visit (Visit 1);\n  6. Subjects treated with leukotriene antagonists\u002Fmodulators prior to screening (subjects treated with stable doses of leukotriene modulators for ≥30 days prior to screening can be enrolled);\n  7. Start allergen immunotherapy within 3 months prior to screening, or plan to start such therapy during the study period or plan to change the therapeutic dose during the study period;\n  8. Have received live attenuated vaccine within 4 weeks prior to screening or plan to receive live attenuated vaccine during the study period;\n  9. Chronic active or acute infection requiring systemic treatment with antibiotics, antivirals, antiparasites, antivirals, or antifungals during the 4 weeks prior to screening, or a viral disease that may not have received antiviral treatment during the 4 weeks prior to screening;(Screening visits can be performed after the patient recovers from infection, but the systemic antibiotic washout period needs to be greater than 2 weeks).\n* Patients with asthma should be excluded if: a. forced expiratory volume in the first second (FEV1) ≤ 50% of the expected normal value, or b.Acute exacerbation of asthma within 90 days prior to screening requiring hospitalization (\\>24 hours), or c.Are using a daily dose of fluticasone or equivalent inhaled glucocorticoids (ICS) greater than 1000mcg;\n* Subjects with asthma were initiated with inhaled corticosteroids within 4 weeks prior to the screening\u002Finduction period (for subjects who could receive a stable dose for at least 4 weeks prior to screening and whose assessed dose could be maintained throughout the study period, inhaled corticosteroids could be fluticasone propionate at a dose ≤1000μg or equivalent doses of other inhaled corticosteroids).\n* Subjects have concomitant medical conditions that prevent them from completing the screening period assessment or evaluating the primary efficacy endpoint, such as:\n\n  1. A deviated nasal septum leads to obstruction of at least one nostril\n  2. Persistent drug rhinitis;\n  3. The diagnosis was eosinophilic granulomatous vasculitis (Churg-Strauss syndrome), granulomatous polyvasculitis (Wegener's granuloma), Young's syndrome, Kartagener syndrome or other ciliary dyskinesia syndrome, cystic fibrosis;\n  4. Suspected or confirmed fungal rhinosinusitis on imaging;\n* Subjects with nasal malignancies and benign tumors (e.g., papilloma, hemangioma, etc.);\n* Subjects who are unable to use MFNS or are allergic or intolerant to Mometasone furoate nasal spray;\n* Subjects with a history of systemic allergy to any biological agent (except local injection site reactions);\n* Pregnant or lactating women;\n* Alcohol, drug and known drug dependence;\n* The subjects had poor compliance in the study and could not complete the study as judged by the researcher;\n* Any medical or psychiatric condition that, in the judgment of the investigator or sponsor medical reviewer, puts the subject at risk, interferes with participation in the study, or interferes with the interpretation of the study results.","ALL","18 Years","75 Years",{"count":20,"type":21},120,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This is a multicenter, randomized, continuing, Phase II expansion trial to evaluate the safety, efficacy, and immunogenicity of two doses of TQH2722 in the long-term treatment of severe chronic sinusitis with or without nasal polyps.",[27],"Chronic Rhinosinusitis","RECRUITING","2026-02-26",{"date":31,"type":32},"2026-02-27","ACTUAL",{"date":34,"type":32},"2024-07-16",{"date":36,"type":21},"2026-06",{"name":38,"class":39},"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","INDUSTRY",28,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":65},"100619114","phase-2-effect-of-chinese-herbal-medicine-nasal-irrigation-on-the-postoperative-care-of-chronic-rhinosinusitis-100619114","NCT07340411","Effect of Chinese Herbal Medicine Nasal Irrigation on the Postoperative Care of Chronic Rhinosinusitis","Breeze Clear","Inclusion Criteria:\n\n* 1\\. Patients with chronic rhinosinusitis who failed medical treatment 2.Patients underwent bilateral primary functional endoscopic sinus surgery.\n\nExclusion Criteria:\n\n* 1\\. Patients with a history of immunodeficiency 2.Patients with a history of sinus surgery 3.Patients who receiving antibiotic treatment within a week before functional endoscopic sinus surgery 4.Patients with a pathological diagnosis of fungal sinusitis 5.Patients with a pathological diagnosis of sinonasal tumor","90 Years",{"count":50,"type":21},80,[24],"Investigators tried to evaluate the efficacy and safety of Chinese herbal medicine nasal irrigation as an adjuvant therapy after FESS.",[27,54],"Postoperative Care","2026-01-05",{"date":57,"type":32},"2026-01-14",{"date":59,"type":32},"2023-07-05",{"date":61,"type":21},"2026-03-31",{"name":63,"class":64},"Taichung Veterans General Hospital","OTHER",1,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":22,"phases":75,"briefSummary":77,"conditions":78,"keywords":79,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":65},"100613723","phase-1-nebulized-nasal-steroids-100613723","NCT07270302","Nebulized Nasal Steroids","Safety and Efficacy of Nebulized Nasal Steroids for the Treatment of Chronic Rhinosinusitis","Inclusion Criteria:\n\n* Age 18 or older that meet diagnostic criteria for CRS with or without polyposis as documented by their recruiting physician.\n* Diagnostic criteria for CRS will be defined according to EPOS criteria of \\>12 weeks of 2 of the following subjective symptoms: nasal blockage or obstruction, rhinorrhea, hyposmia, or facial pain\u002Fpressure AND objective evidence of CRS on either nasal endoscopy or CT scan\n\nExclusion Criteria:\n\n* Patients who have previously undergone sinus surgery\n* Severe polyposis; defined as Lund Kennedy endoscopy score greater than 1\n* Patients who are currently using or who have previously used biologic medications for their nasal polyps. These medications include: dupilumab, omalizumab, mepolizumab, tezepelumab, or depemokimab\n* Inability to complete surveys in English\n* known comorbid mucociliary disease\n* known adrenal disease or other HPA dysfunction\n* patients taking oral corticosteroids for other medical conditions\n* oral antibiotic administration within 2 weeks of study participation\n* a baseline SNOT-22 score less than 9, due to inability to achieve the MCID",{"count":74,"type":21},50,[76,24],"PHASE1","The goal of the proposed project is to assess the efficacy, safety, and patient experience of budesonide administered via the NasoNeb system for medical management of CRS. The authors propose a randomized controlled trial of nebulized budesonide via the NasoNeb compared against budesonide lavage.",[27],[80,81,82,83],"Otolaryngology","Pharmacology","Pharmacy","intranasal steroid sprays","NOT_YET_RECRUITING","2025-11-26",{"date":87,"type":32},"2025-12-08",{"date":89,"type":21},"2025-12",{"date":91,"type":21},"2026-05",{"name":93,"class":64},"Washington University School of Medicine",{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":16,"minAge":100,"maxAge":101,"enrollmentInfo":102,"targetDuration":4,"studyType":22,"phases":104,"briefSummary":106,"conditions":107,"keywords":108,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":65},"100597791","efficacy-of-erythromycin-phonophoresis-on-chronic-rhinosinusitis-100597791","NCT07063082","Efficacy Of Erythromycin Phonophoresis on Chronic Rhinosinusitis","Inclusion Criteria:\n\n* Age range between 25-50 years.\n* Male and female patients will participate in the study.\n* All patients have chronic rhinosinusitis.\n* All patients enrolled in the study will have their informed consent.\n* CT will include at least affection of maxillary sinus.\n\nExclusion Criteria:\n\n* Patients with pacemaker\n* Patients diagnosed with cancer.\n* Pregnant women\n* Patients with impaired vascular circulation\n* Patients who suffer from mental or psychological disorders.\n* Patients with any systemic diseases that may interfere with the objectives of the study.\n* Congenital defects on face and nose.\n* Fracture of nose or face.\n* Polypoidal patients.\n* Allergic patients.\n* Previous nasal surgery.","25 Years","50 Years",{"count":103,"type":21},90,[105],"NA","The purpose of the study is to evaluate the therapeutic effect of erythromycin phonophoresis in reducing chronic rhinosinusitis.",[27],[109,110,111],"Erythromycin","Phonophoresis","ultrasound","2025-07-02",{"date":114,"type":32},"2025-07-14",{"date":116,"type":21},"2025-07-07",{"date":118,"type":21},"2025-09-15",{"name":120,"class":64},"Cairo University",{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":128,"enrollmentInfo":129,"targetDuration":4,"studyType":22,"phases":131,"briefSummary":132,"conditions":133,"keywords":135,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":65},"100580419","the-effect-of-modified-olfactory-training-on-postoperative-olfactory-dysfunction-in-patients-with-crs-100580419","NCT06837051","The Effect of Modified Olfactory Training on Postoperative Olfactory Dysfunction in Patients With CRS","Protocol for a Randomized Controlled Trial Evaluating the Effect of Modified Olfactory Training on Postoperative Olfactory Dysfunction in Patients With Chronic Rhinosinusitis","Inclusion Criteria:\n\n1. A diagnosis of CRSsNP based on the European Position Paper on Rhinosinusitis and Nasal Polyps 2020 (EPOS20).\n2. The duration after endoscopic sinus surgery is 3months.\n3. Olfactory dysfunction confirmed with the Sniffin's Sticks psychophysical test (TDI score≦30.5) .\n4. Willingness to participate in this study and sign the informed consent form (ICF).\n\nExclusion Criteria:\n\n1. Patients with olfactory impairment due to traumatic, congenital, toxic\u002Fdrug-induced causes, tumors, or post-upper respiratory infections.\n2. Lund-Mackay olfactory cleft score \\> 0.\n3. Patients with severe comorbidities, such as malignant tumors.\n4. Current or planned pregnancy prior to the end of study.\n5. Patients who are unable to complete the study or are unable to comply with the requirements of the study (such as inability to tolerate olfactory function testing and treatment, memory or behavioral abnormalities, depression, smoking, heavy alcohol use, previous delinquent behavior)","80 Years",{"count":130,"type":21},213,[105],"The goal of this clinical trial is to validate the effectiveness of the modified olfactory training device, the main questions it aims to answer are:\n\nIs it possible that the device can treat postoperative olfactory dysfunction in patients with chronic sinusitis? Compared to the conventional device, how efficient is the modified olfactory training device for treating postoperative olfactory dysfunction in patients with chronic sinusitis?",[134,27],"Olfactory Dysfunction",[136,137,138,139],"olfactory dysfunction","chronic rhinosinusitis","endoscopic sinus surgery","olfactory training","2025-02-14",{"date":142,"type":32},"2025-02-20",{"date":144,"type":21},"2025-03-14",{"date":146,"type":21},"2027-03-14",{"name":148,"class":64},"Peking University Third Hospital",{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":157,"targetDuration":159,"studyType":160,"phases":4,"briefSummary":161,"conditions":162,"keywords":163,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":65},"100511149","rhinosinusitis-italian-network-the-italian-registry-for-severe-uncontrolled-chronic-rhinosinusitis-100511149","NCT05935683","Rhinosinusitis Italian Network: the Italian Registry for Severe, Uncontrolled Chronic Rhinosinusitis","Rhinosinusitis Italian Network (RINET): the Italian Registry for Severe, Uncontrolled Chronic Rhinosinusitis","RINET","Inclusion Criteria:\n\n* Participants with a confirmed diagnosis of bilateral Chronic Rhinosinusitis that have at least three (in case of patients previously treated with surgical approaches) or four (in case of patients never treated with nasal sinus surgery) of the following criteria:\n\n  * Evidence of type 2 inflammation (at least 250 blood eosinophils per microliter and \u002F or at least 10 eosinophils \u002F HPF from a histological sample of sinus mucosa and \u002F or at least one finding of moderate eosinophilia on nasal cytology and \u002F or total serum IgE \\>100 IU \u002F ml);\n  * at least two Short courses of systemic corticosteroids or lorg-term Systemic Corticosteroids therapy for Chronic Rhinosinusitis;\n  * Significant deterioration in the quality of life (Sinonasal Outcome Test 22 - SNOT-22\\>= 40 and \u002F or Visual Analogue Scale - Global VAS of symptoms\\>= 5);\n  * Loss of Smell (VAS for hyposmia\\> = 7)\n\nExclusion Criteria:\n\n\\-",{"count":158,"type":21},5000,"10 Years","OBSERVATIONAL","This observatory aims to collect, as widely as possible, the Italian cases of patients with uncontrolled CRS. Patient will be enrolled by the centers of the Italian Network of Rhinosinusitis (Rhinosinusitis Italian Network: RINET), and they will be treated using a multidisciplinary team approach (allergists, otolaryngologists and pneumologists) in a real-world clinical set-up.\n\nThis real-life chronic rhinosinusitis registry aims at longitudinal data collection from patients attending specialist care centres across Italy.",[27],[164,165,166,167,168,169,170,171],"chronic rhinosinusitis with nasal polyps","chronic rhinosinusitis without nasal polyps","Otorhinolaryngologic Diseases","Respiratory Tract Diseases","Paranasal Sinus Diseases","Sinusitis","Nose Diseases","chronic rhinosinusitis (diagnosis)","2024-07-18",{"date":174,"type":32},"2024-07-19",{"date":176,"type":32},"2021-11-01",{"date":178,"type":21},"2031-10-31",{"name":180,"class":64},"Italian Academy of Rhinology"]